Lung cancer combo trial halted early

NCT ID NCT02257619

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Apr 24, 2026 · Last updated May 14, 2026 · Updated 2 times

Summary

This study tested whether adding itacitinib to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. Only 9 people took part before the trial was stopped early. The main goals were to check safety and find the right dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Study site

Hot Springs, Arizona, United States
Study site

Los Angeles, California, United States
Study site

Washington D.C., District of Columbia, United States
Study site

Orlando, Florida, United States
Study site

Detroit, Michigan, United States
Study site

Pascagoula, Mississippi, United States
Study site

Kansas City, Missouri, United States
Study site

Omaha, Nebraska, United States
Study site

Lebanon, New Hampshire, United States
Study site

Goldsboro, North Carolina, United States
Study site

Cleveland, Ohio, United States
Study site

Gettysburg, Pennsylvania, United States
Study site

Hershey, Pennsylvania, United States
Study site

Pawtucket, Rhode Island, United States
Study site

Spartanburg, South Carolina, United States
Study site

Round Rock, Texas, United States

Conditions

Explore the condition pages connected to this study.

NSCLC, NON-SMALL-CELL LUNG CARCINOMA